No description available.

No description available.

by Liu Fang. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1996. / Includes bibliographical references (leaves 159-178). / ACKNOWLEGEMENTS --- p.i / ABSTRACT --- p.ii / TABLE OF CONTENTS --- p.v / LIST OF TABLES --- p.ix / LIST OF FIGURES --- p.xi / ABBREVIATIONS --- p.xiv / Chapter Chapter 1. --- General Introduction --- p.1 / Chapter Chapter 2. --- Literature Review --- p.7 / Chapter 2.1. --- Biologically active polysaccharides --- p.7 / Chapter 2.2. --- Antitumor activities of polysaccharides --- p.11 / Chapter 2.2.1. --- In vivo studies --- p.11 / Chapter 2.2.2. --- In vitro studies --- p.15 / Chapter 2.3. --- Antitumor mechanisms of polysaccharides --- p.17 / Chapter 2.4. --- Structure and antitumor activities of polysaccharides --- p.25 / Chapter 2.4.1. --- The effect of molecular mass --- p.26 / Chapter 2.4.2. --- The impact of branching configuration --- p.21 / Chapter 2.4.3. --- The relationship between antitumor activity and conformation --- p.28 / Chapter 2.4.4. --- Improvement of antitumor activity by chemical modification --- p.29 / Chapter 2.5. --- Other biological activities --- p.30 / Chapter 2.5.1. --- Antiviral activity --- p.30 / Chapter 2.5.2. --- Antimicrobial activity --- p.31 / Chapter 2.5.3. --- Free radical scavenging activity --- p.32 / Chapter 2.5.4. --- Hepatic protective effect --- p.32 / Chapter Chapter 3. --- Isolation and Characterization of a Polysaccharide-Protein Complex (PSPC) from Tricholoma lobayense --- p.34 / Chapter 3.1. --- Introduction --- p.34 / Chapter 3.2. --- Materials and methods --- p.36 / Chapter 3.2.1. --- Strain --- p.36 / Chapter 3.2.2. --- Culture conditions --- p.36 / Chapter 3.2.3. --- Extraction of T. lobayense --- p.39 / Chapter 3.2.4. --- Purification of polysaccharide-protein complex --- p.40 / Chapter 3.2.5. --- Molecular mass determination --- p.43 / Chapter 3.2.6. --- High performance liquid chromatography --- p.43 / Chapter 3.2.7. --- SDS-polyacrylamide gel electrophoresis --- p.44 / Chapter 3.2.8. --- Ultraviolet scanning --- p.44 / Chapter 3.2.9. --- Chemical analysis --- p.45 / Chapter 3.2.10. --- Experimental animals --- p.47 / Chapter 3.2.11. --- In vivo antitumor assay --- p.48 / Chapter 3.2.12. --- Safety tests --- p.49 / Chapter 3.2.13. --- Statistical analysis --- p.51 / Chapter 3.3. --- Results --- p.51 / Chapter 3.3.1. --- Extraction and purification --- p.51 / Chapter 3.3.2. --- Biochemical analysis --- p.52 / Chapter 3.3.3. --- Chemical analysis --- p.60 / Chapter 3.3.4. --- In vivo antitumor activity --- p.68 / Chapter 3.3.5. --- Safety evaluation --- p.68 / Chapter 3.4. --- Discussion --- p.75 / Chapter 3.5. --- Summary --- p.84 / Chapter Chapter 4. --- "Immunomodulating, Antitumor and other Biological Activities of Polysaccharide-Protein Complex (PSPC) from Tricholoma lobayense" --- p.85 / Chapter 4.1. --- Introduction --- p.85 / Chapter 4.2. --- Materials and methods --- p.87 / Chapter 4.2.1. --- Experimental animals --- p.87 / Chapter 4.2.2. --- Cultivation of tumor cells --- p.87 / Chapter 4.2.3. --- Preparation of peritoneal exudate cells and splenocytes --- p.87 / Chapter 4.2.4. --- Mitogenic response of T cells --- p.89 / Chapter 4.2.5. --- Responses of peritoneal exudate cells --- p.89 / Chapter 4.2.6. --- In vitro antitumor assay --- p.92 / Chapter 4.2.7. --- Transmission electron microscope --- p.93 / Chapter 4.2.8. --- Evaluation of other biological activities --- p.94 / Chapter 4.2.9. --- Statistical analysis --- p.99 / Chapter 4.3. --- Results --- p.99 / Chapter 4.3.1. --- Immunomodulating activity --- p.99 / Chapter 4.3.2. --- In vitro antitumor action --- p.107 / Chapter 4.3.3. --- Observation on tumor regression induced by PSPC --- p.107 / Chapter 4.3.4. --- Other biological actions --- p.112 / Chapter 4.4. --- Discussion --- p.121 / Chapter 4.4.1. --- Immunomodulating activity --- p.121 / Chapter 4.4.2. --- Antitumor activity --- p.125 / Chapter 4.4.3. --- Other biological activities --- p.127 / Chapter 4.5. --- Summary --- p.130 / Chapter Chapter 5. --- Induction of Gene Expression of Immunomodulating Cytokines by Polysaccharide-Protein Complex (PSPC) from Tricholoma lobayense --- p.132 / Chapter 5.1. --- Introduction --- p.132 / Chapter 5.2. --- Materials and methods --- p.135 / Chapter 5.2.1. --- Experimental animals --- p.135 / Chapter 5.2.2. --- Preparation of peritoneal exudate cells and splenocytes --- p.136 / Chapter 5.2.3. --- RNA extraction --- p.137 / Chapter 5.2.4. --- Reverse transcription- polymerase chain reaction --- p.137 / Chapter 5.2.5. --- Dot blot --- p.138 / Chapter 5.2.6. --- Hybridization --- p.141 / Chapter 5.3. --- Results --- p.142 / Chapter 5.3.1. --- mRNA phenotyping of cytokines and cytokine receptors in normal mice --- p.142 / Chapter 5.3.2. --- mRNA phenotyping of cytokines and cytokine receptors in tumor-bearing mice --- p.142 / Chapter 5.4. --- Discussion --- p.150 / Chapter 5.5. --- Summary --- p.153 / Chapter Chapter 6. --- General Discussion and Conclusion --- p.155 / REFERENCES --- p.159

O anticorpo anti-proteína P ribossomal é um dos marcadores sorológicos do lúpus eritematoso sistêmico, previamente associado a glomerulonefrite lúpica classe V (ISN-RPS). Neste trabalho foi avaliado o prognóstico renal em pacientes que possuem positividade para este anticorpo. Sessenta pacientes foram avaliados para parâmetros de sobrevida renal. Onze pacientes (18%) apresentaram positividade sorológica exclusiva para anticorpo anti-P ribossomal e vinte e oito pacientes (47%) para anti-dsDNA. Ao final do período de seguimento, foi observado que os pacientes anti-P positivos apresentaram uma maior sobrevida renal (11,0 ± 4,5 vs. 9,2 ± 4,5 anos, p=0,03) quando comparados aqueles anti-P negativos, assim como menor frequência de necessidade de terapia substitutiva renal (0 vs. 35% p = 0,025). Pacientes anti-P positivos apresentaram também maior frequência de classe V (91% vs. 31%, p < 0.001) e menor incidência de alterações proliferativas (45% vs. 82%, p = 0,021) na avaliação da biópsia renal quando comparados aos pacientes sem a positividade para este anticorpo. Os dados reforçam a hipótese de que o anticorpo anti-P é um marcador útil de um melhor prognóstico renal em pacientes portadores de lúpus eritematoso sistêmico / Antibodies to ribossomal P proteins are one of the serologic markers of systemic lupus erythematosus, previously described as associated to class V lupus glomerulonephritis (ISN-RPS). Our study assessed renal prognosis in patients with anti-P antibodies. Sixty consecutive SLE patients with biopsyproven nephritis (2004 ISN/RPS) were evaluated for renal survival parameters. Eleven patients (18%) had exclusive anti-P positivity and 28 (47%) patients anti-dsDNA. The post-biopsy follow-up analysis demonstrated that anti-P positive patients disclosed better renal survival (11.0 ± 4.5 vs. 9.2 ± 4.5 years, p = 0.03) as well as lower frequency of patients requiring dialysis (0 vs. 35% p = 0.025). The frequency of class V nephritis was higher in anti-P positive patients (91% vs. 31%, p < 0.001) and the occurrence of proliferative lesions at biopsy was lower in these patients (45% vs. 82%, p=0.021). Our data supports the notion that anti-P antibody is a valuable marker to predict a better long-term renal outcome in lupus patients

O anticorpo anti-proteína P ribossomal é um dos marcadores sorológicos do lúpus eritematoso sistêmico, previamente associado a glomerulonefrite lúpica classe V (ISN-RPS). Neste trabalho foi avaliado o prognóstico renal em pacientes que possuem positividade para este anticorpo. Sessenta pacientes foram avaliados para parâmetros de sobrevida renal. Onze pacientes (18%) apresentaram positividade sorológica exclusiva para anticorpo anti-P ribossomal e vinte e oito pacientes (47%) para anti-dsDNA. Ao final do período de seguimento, foi observado que os pacientes anti-P positivos apresentaram uma maior sobrevida renal (11,0 ± 4,5 vs. 9,2 ± 4,5 anos, p=0,03) quando comparados aqueles anti-P negativos, assim como menor frequência de necessidade de terapia substitutiva renal (0 vs. 35% p = 0,025). Pacientes anti-P positivos apresentaram também maior frequência de classe V (91% vs. 31%, p < 0.001) e menor incidência de alterações proliferativas (45% vs. 82%, p = 0,021) na avaliação da biópsia renal quando comparados aos pacientes sem a positividade para este anticorpo. Os dados reforçam a hipótese de que o anticorpo anti-P é um marcador útil de um melhor prognóstico renal em pacientes portadores de lúpus eritematoso sistêmico / Antibodies to ribossomal P proteins are one of the serologic markers of systemic lupus erythematosus, previously described as associated to class V lupus glomerulonephritis (ISN-RPS). Our study assessed renal prognosis in patients with anti-P antibodies. Sixty consecutive SLE patients with biopsyproven nephritis (2004 ISN/RPS) were evaluated for renal survival parameters. Eleven patients (18%) had exclusive anti-P positivity and 28 (47%) patients anti-dsDNA. The post-biopsy follow-up analysis demonstrated that anti-P positive patients disclosed better renal survival (11.0 ± 4.5 vs. 9.2 ± 4.5 years, p = 0.03) as well as lower frequency of patients requiring dialysis (0 vs. 35% p = 0.025). The frequency of class V nephritis was higher in anti-P positive patients (91% vs. 31%, p < 0.001) and the occurrence of proliferative lesions at biopsy was lower in these patients (45% vs. 82%, p=0.021). Our data supports the notion that anti-P antibody is a valuable marker to predict a better long-term renal outcome in lupus patients